

**PRESS RELEASE 10<sup>th</sup> February 2010: Beremans Ltd review of dengue vaccines published in Current Opinion in Molecular Therapeutics**

Beremans Ltd, the Cambridge-based business intelligence company ([www.beremans.com](http://www.beremans.com)), today announced publication of an invited review on progress in dengue vaccines. The paper, entitled "Recent progress in dengue vaccine research and development", is published in the peer-reviewed journal Current Opinion in Molecular Therapeutics (Curr Opin Mol Ther. 2010;12(1):31-8), and presents an analysis of recent efforts aimed at developing vaccines against dengue fever. The commercial prospects associated with public and private sector dengue vaccines, both in the developed and the developing world, have recently been published in a separate Beremans report (<http://www.beremans.com/reports/reportDetail.asp?id=1>).

Dr Nicholas Miller, Managing Director of Beremans Ltd, said "Being invited to write a review on this topic for a Current Opinion journal is an indication of our reputation in the vaccine field, especially with regard to vaccines relevant to travellers. It supports our claim that we follow and understand the implications of critical developments in the areas in which we specialise, which enables us to execute business intelligence projects from a position of strength. Having a good understanding of the science and technology of dengue vaccine development of course feeds into other projects, not least our report on the commercial prospects for dengue vaccines, which is a highly detailed market assessment based on, *inter alia*, our proprietary model of international travel from over 20 developed economies to over 100 endemic countries."

Dengue fever is a disease associated primarily with urban and peri-urban regions in tropical and sub-tropical regions, and is thought to be responsible for over 35 million symptomatic infections annually. The incidence and severity of dengue infections appear to be growing, making it a major global public health concern. The review may be accessed via the Current Opinion in Molecular Therapeutics journal website at <http://www.biomedcentral.com/curropinmolther/>; and the Beremans report on commercial prospects for dengue vaccines is available at <http://www.beremans.com/reports/reportDetail.asp?id=1>.

Beremans Ltd is a Cambridge-based company that provides business intelligence services for the Life Sciences sector. Areas of particular strength include vaccines, oncology, regenerative medicine and drug discovery. For further information please email Dr. Nicholas Miller, Managing Director, Beremans Ltd: [nm01@beremans.com](mailto:nm01@beremans.com).

General contact information:

[info@beremans.com](mailto:info@beremans.com)

0044 1223 969286